Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: J. David who wrote (305)	8/8/1998 12:25:00 AM
From: Wen Lee	Read Replies (1) \| Respond to of 942

Checked the Yahoo insider sale page. WLA's president and COO planned to sale most of his shares. Its chairman and CEO only hold 26000 shares. Should we worry of this?

To: J. David who wrote (305)	8/8/1998 8:05:00 PM
From: Zoltar	Respond to of 942

hi all. im new to warner lambert, i bought shares on friday. my broker at merrill told me that of all the drug stocks wla was the best value. so what are year end predictions for this stock. do the usually meet earnings. thanks.

To: J. David who wrote (305)	8/10/1998 6:16:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Options Report: Bottom-Fishers, Rebound Traders Dominate August 10, 1998 3:57 PM By Steven M. Sears NEW YORK (Dow Jones)--Bottom-fishing and trading rebounds in stock prices were the main methods options traders used Monday to enter a thinly traded market. There weren't many other reasons to take a stand as the stock market drifted in a tight range during the session. Trading volume at the Chicago Board Options Exchange illustrated the lack of themes. About 454,000 contracts traded, compared with average volume of about 800,000 contracts. Elsewhere in the options market: - Merck & Co., Pfizer Inc. and Warner-Lambert Co. all saw action, primarily in call contracts that would become valuable if the drug stocks continued to advance. Merck's most active contract, the August 125 call, gained 1 5/8 to 3 7/8 on volume of 583 contracts, compared with open inters of 4,542 contracts. The stock gained 2 5/16 to 126 3/16. Pfizer's most active contract, the September 105 calls, which gained 1/2 to 5 3/8 on volume of 1,712 contracts, compared with open interest of 4,511 contracts. The stock gained 1 to 104 1/2. Warner-Lambert's most active contract, the September 75 call, gained 1 to 4 on volume of 1,671 contracts, compared with open interest of 2,247 contracts. Warner-Lambert's shares were up 1 7/8 at 73 1/2. - Immunex Corp. was active for a second session as institutional firms traded the biopharmaceutical company's calls as the company began a two-day annual meeting with stock analysts. Some traders sold August calls because they thought the bloated volatilities would fall after the anticipation of the meeting fades. Volatility, which indicates how likely the underlying stock price is to move in either direction, generally increases before analyst meetings or other events that could generate news that effects the stock price. An Immunex trader said other firms are positioning for the September 16 review of Enbrel, the company's rheumatoid arthritis drug, by a Food and Drug Administration advisory committee. Not everyone is taking a purely speculative approach to Immunex's options. One trader used a bull spread strategy that limits his risk and profit. He sold September 70 calls and bought September 65 calls. The September 70 call gained 1 3/8 to 5 3/4 on volume of 110 contracts, compared with open interest of 870 contracts. The September 65 call gained 1 7/8 to 8 on volume of 110 contracts, compared with open interest of 464 contracts. smartmoney.com